Objective To assess the safety of co-immunization of group A and group C meningococcal polysaccharide conjugate vaccine （MPCV-AC） and hepatitis B vaccine（HepB）. Methods The data on adverse event following immunization（AEFI） and vaccination with MPCV-AC and HepB among age-eligible children in Anhui Province，China from 2020 to 2022 were obtained through the National Immunization Information System and Anhui Provincial Immunization Information System. The reported incidence rates of AEFI were compared among children who received the two vaccines simultaneously and separately. Results The reported incidence rates of AEFI were 48.03/10⁵（280 cases） following co-immunization of MPCV-AC （1^st dose） and HepB（3^rd dose），56.37/10⁵（314 cases） following MPCV-AC（1^st dose），and 51.96/10⁵（283 cases） following HepB（3^rd dose）. The incidence rates of common reactions in the three groups were 43.91/10⁵（256 cases），51.35/10⁵（286 cases），and 48.65/10⁵（265 cases），respectively；the incidence rates of adverse events in the three groups were 4.12/10⁵ （24 cases），4.85/10⁵（27 cases），and 3.30/10⁵（18 cases），respectively. There were no significant differences between the co-immunization group and the separate vaccination groups in the risk of AEFI，common reactions，and adverse events. Conclusion Co-immunization of MPCV-AC and HepB does not increase the risk of AEFI，which can serve as a scientific basis for co-immunization of MPCV-AC and HepB in 6-month-old children.